title: Discovery of N-[(1R,2S,5S)-2-{[(5-chloroindol-2-yl)carbonyl]amino}-5-(dimethylcarbamoyl)cyclohexyl]-5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamide hydrochloride: a novel, potent and orally active direct inhibitor of factor Xa.
abstract: In the early 1990's, we reported on the low-molecular selective fXa inhibitor DX-9065a having two amidino groups. However, it had poor oral bioavailability due to its strong basic amidino groups. To obtain fXa inhibitors with improved oral bioavailability, we investigated various non-amidino fXa inhibitors and finally discovered cis-1,2-diaminocyclohexane derivative 4c to have potent fXa inhibition, promising anticoagulant activity, and good oral bioavailability, compared with amidino compound DX-9065a. In addition, we will discuss the influence of the third substituent on the cyclohexane ring on anti-fXa activity, anticoagulant activity, PK profile, and lipophilicity.
authors.affiliation: R&D Division, Daiichi Sankyo Co., Ltd., 1-2-58, Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan. nagata.tsutomu.ni@daiichisankyo.co.jp
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Nagata
authors.forename: Toshiharu
authors.initials: T
authors.lastname: Yoshino
authors.forename: Noriyasu
authors.initials: N
authors.lastname: Haginoya
authors.forename: Kenji
authors.initials: K
authors.lastname: Yoshikawa
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Nagamochi
authors.forename: Syozo
authors.initials: S
authors.lastname: Kobayashi
authors.forename: Satoshi
authors.initials: S
authors.lastname: Komoriya
authors.forename: Aki
authors.initials: A
authors.lastname: Yokomizo
authors.forename: Ryo
authors.initials: R
authors.lastname: Muto
authors.forename: Mitsuhiro
authors.initials: M
authors.lastname: Yamaguchi
authors.forename: Ken
authors.initials: K
authors.lastname: Osanai
authors.forename: Makoto
authors.initials: M
authors.lastname: Suzuki
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Kanno
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000925:Anticoagulants / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology*; D001682:Biological Availability; D018360:Crystallography, X-Ray; D015951:Factor Xa / Q000378:metabolism; D065427:Factor Xa Inhibitors; D000882:Haplorhini; D006801:Humans; D007211:Indoles / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology*; D009281:Naphthalenes / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology; D011422:Propionates / Q000138:chemical synthesis / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology*; D011485:Protein Binding; D013844:Thiazoles / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology*
chemical_list: C086910:(2S)-2-(4-(((3S)-1-acetimidoyl-3-pyrrolidinyl)oxy)phenyl)-3-(7-amidino-2-naphtyl)propanoic acid; D000925:Anticoagulants; D065427:Factor Xa Inhibitors; D007211:Indoles; C539859:N-(2-(((5-chloroindol-2-yl)carbonyl)amino)-5-(dimethylcarbamoyl)cyclohexyl)-5-methyl-4,5,6,7-tetrahydrothiazolo(5,4-c)pyridine-2-carboxamide; D009281:Naphthalenes; D011422:Propionates; D013844:Thiazoles; D015951:Factor Xa